Heron Therapeutics Initiates Phase 3 Label Expansion Study of SUSTOL(TM)
Business Wire - Mon Mar 31, 7:01AM CDT
Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL(TM) (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy. This Phase 3 clinical trial will evaluate SUSTOL for the prevention of delayed-onset CINV in patients receiving highly emetogenic chemotherapy (HEC) agents and is designed to support expansion of the expected label for SUSTOL in the delayed-onset HEC setting.
Heron Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results and Highlights Recent Corporate Progress
Business Wire - Wed Mar 05, 7:01AM CST
Heron Therapeutics, Inc. (NASDAQ:HRTX), a specialty pharmaceutical company, today reported fourth quarter and full year 2013 financial results and highlighted recent corporate progress.
Why Heron (HRTX) Has A Bright Short-Term Future? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jan 29, 7:37AM CST
Heron has seen its Zacks Rank move up from Sell to Buy over the past four weeks
Heron Therapeutics' resubmission on NDA for Sustol to US FDA delayed
M2 - Tue Jan 28, 5:33AM CST
Specialty pharmaceutical company Heron Therapeutics Inc (NCM:HRTX) on Monday announced an approximate one-quarter delay to its timeline for the resubmission of the new drug application (NDA) for Sustol to the US Food and Drug Administration (FDA), the company's product candidate for chemotherapy-induced nausea and vomiting (CINV).
Heron Therapeutics Provides Update on Sustol Resubmission
Business Wire - Mon Jan 27, 7:00AM CST
Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today announced an approximate one-quarter delay to the Company's timeline for the resubmission of the new drug application (NDA) for Sustol(R) to the U.S. Food and Drug Administration (FDA), the Company's product candidate for chemotherapy-induced nausea and vomiting (CINV).